Vega Ana, Torres Josema, Torres María, Cameselle-Teijeiro José, Macia Manuel, Carracedo Angel, Pulido Rafael
Unidad de Medicina Molecular (INGO), Hospital Clínico Universitario, Santiago de Compostela, Spain.
J Invest Dermatol. 2003 Dec;121(6):1356-9. doi: 10.1111/j.1523-1747.2003.12638.x.
Cowden disease, also known as multiple hamartoma syndrome, is a rare disease inherited in an autosomal dominant pattern, which confers a high risk of developing breast and thyroid carcinomas. Mutations in PTEN, a tumor suppressor gene located on chromosome 10q23, have been identified in patients with Cowden disease. In this work, the direct sequencing of all coding regions of the PTEN gene led us to the identification of N48K, a new germline PTEN missense mutation, in a patient suffering from Cowden disease. The genetic analysis of 200 chromosomes from healthy individuals revealed that the variant was not common in our population. Moreover, by functional analysis we found that the ability of PTEN N48K mutant protein to inhibit the activation of the proto-oncogene PKB/Akt was impaired, supporting the involvement of N48K mutation in Cowden disease. Loss of heterozygosity using three microsatellites (D10S215, D10S541, and D10S564) and the complete sequence analysis of PTEN exons in breast and endometrial tumor samples from the same patient were also carried out in an attempt to identify additional PTEN somatic mutations. The lack of loss of heterozygosity or additional mutations in tumor samples suggests that abnormalities of the regulatory regions of the PTEN gene or haplo-insufficiency might occur in tumors from Cowden disease patients.
考登病,也称为多发性错构瘤综合征,是一种以常染色体显性模式遗传的罕见疾病,会增加患乳腺癌和甲状腺癌的风险。在考登病患者中已鉴定出位于10q23染色体上的肿瘤抑制基因PTEN发生突变。在这项研究中,对PTEN基因所有编码区进行直接测序后,我们在一名考登病患者中鉴定出一种新的种系PTEN错义突变N48K。对200条来自健康个体的染色体进行基因分析后发现,该变异在我们的人群中并不常见。此外,通过功能分析我们发现,PTEN N48K突变蛋白抑制原癌基因PKB/Akt激活的能力受损,这支持了N48K突变与考登病有关。我们还使用三个微卫星(D10S215、D10S541和D10S564)进行杂合性缺失分析,并对同一名患者的乳腺和子宫内膜肿瘤样本中的PTEN外显子进行完整序列分析,以试图鉴定其他PTEN体细胞突变。肿瘤样本中缺乏杂合性缺失或其他突变表明,考登病患者的肿瘤中可能发生PTEN基因调控区异常或单倍体不足。